Abstract View

Author(s): Shivangi Yadav*1, Patel Dhara2, Patel Grishma3, Rashmi Rajeghorpade4, Dhananjay Meshram5

Email(s): 1yadavshivangi445@gmail.com

Address:

    Department of Pharmaceutical Quality Assurance, Pioneer Pharmacy College-390019,Gujarat India

Published In:   Volume - 5,      Issue - 6,     Year - 2026

DOI: https://doi.org/10.71431/IJRPAS.2026.5611  

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Pharmaceuticals have been credited with curing many diseases; however, there are unintentional exposures to toxins from drugs that have occurred at the manufacturing site, which can pose considerable risks to employees' health through unintentional contact. Thus, there is a need for us to protect workers from these dangers by limiting their level of exposure. This is done by defining the level of exposure that is acceptable or "occupational exposure limit" (OEL). OEL is the airborne concentration(s) over eight hours of work per day, for either a Working Lifetime). A definition of "acceptable daily exposure"(ADE) and "permitted daily exposure"(PDE) are established to define what is the maximum quantity of a pharmaceutical ingredient that may be present as a contaminant in another product, without it being harmful to the health of the end user. When adverse effects related to the exposure to an ingredient can be identified, the Point of Departure (Pod) that would be used in risk assessment is selected. Composite safety factors must be used in order to derive both ADE and PDE values. Each composite safety factor must include a variety of uncertainties identified at the time of establishment of the drug(s) being evaluated.

Cite this article:
Shivangi Yadav, Patel Dhara, Patel Grishma, Rashmi Rajeghorpade, Dhananjay Meshram. Optimizing OEL and ADE/PDE Compliance in Pharma. IJRPAS, June 2026; 5(6): 126-145.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2026.5611


References not available.

Related Images:



Recent Images



Nanotechnology in Cosmetic Formulations: Recent Advances and Safety Concerns
Analysis of Pro-Inflammatory Cytokines Response Among Typhoid Patients Co-Infection with Plasmodium falciparum In Khartoum State -Sudan
Optimizing OEL and ADE/PDE Compliance in Pharma
Formulation and Evaluation of Quercetin Nanoemulsion Gel for Rheumatoid Arthritis
Formulation and Evaluation of Herbal Oil -Roghan-e-Turb: A Traditional Unani Formulation for Analgesic Activity
Formulation and Evaluation of Anti-Pimple Herbal Serum Enriched with Tulsi, Turmeric, Aloe Vera, Neem
Formulation, Optmization and Evaluation of Curcuma longa and Piper nigrum Hydrogel
A Review on Emerging Technologies in Monitoring and Diagnosing Immune Thrombocytopenia (ITP): Current Trends and Future Directions
Phytochemical Characterisation, In Silico Androgen Receptor Inhibitory Activity, and Fertility-Enhancing Potential of Aqueous–Ethanol Root Extract of Triclisia subcordata Oliv.
Formulation of Effervescent Granules from Bangkal Tree (Nauclea orientalis) Leaf Extract: A Potential  Larvicide Against Aedes Aegypti

Tags